SK3592001A3 - Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas - Google Patents

Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas Download PDF

Info

Publication number
SK3592001A3
SK3592001A3 SK359-2001A SK3592001A SK3592001A3 SK 3592001 A3 SK3592001 A3 SK 3592001A3 SK 3592001 A SK3592001 A SK 3592001A SK 3592001 A3 SK3592001 A3 SK 3592001A3
Authority
SK
Slovakia
Prior art keywords
pharmaceutically acceptable
acceptable salt
adhd
treatment
receptor agonist
Prior art date
Application number
SK359-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Elisa Rose Jackson
Stafford Mclean
Stevin Howard Zorn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SK3592001A3 publication Critical patent/SK3592001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK359-2001A 1998-09-21 1999-09-03 Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas SK3592001A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10119198P 1998-09-21 1998-09-21
US10386898P 1998-10-12 1998-10-12
PCT/IB1999/001503 WO2000016777A1 (fr) 1998-09-21 1999-09-03 Substances a usage pharmaceutique destinees au traitement de la maladie de parkinson, de l'hyperactifvite avec deficit de l'attention et du microadenome

Publications (1)

Publication Number Publication Date
SK3592001A3 true SK3592001A3 (en) 2001-12-03

Family

ID=26798000

Family Applications (1)

Application Number Title Priority Date Filing Date
SK359-2001A SK3592001A3 (en) 1998-09-21 1999-09-03 Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas

Country Status (38)

Country Link
US (2) US6300329B1 (fr)
EP (1) EP1115402A1 (fr)
JP (1) JP2002526448A (fr)
KR (3) KR100468340B1 (fr)
CN (1) CN1319013A (fr)
AP (1) AP1456A (fr)
AR (1) AR029739A1 (fr)
AU (1) AU760230B2 (fr)
BG (1) BG105445A (fr)
BR (1) BR9913975A (fr)
CA (1) CA2344670A1 (fr)
CO (1) CO5140075A1 (fr)
CZ (1) CZ20011006A3 (fr)
DZ (1) DZ2894A1 (fr)
EA (2) EA200301063A1 (fr)
EE (1) EE200100179A (fr)
GE (1) GEP20033081B (fr)
GT (1) GT199900154A (fr)
HN (1) HN1999000146A (fr)
HR (1) HRP20010209A2 (fr)
HU (1) HUP0103691A3 (fr)
ID (1) ID28028A (fr)
IL (2) IL141507A0 (fr)
IS (1) IS5852A (fr)
MA (1) MA26690A1 (fr)
MY (1) MY127939A (fr)
NO (1) NO20011409L (fr)
NZ (1) NZ509855A (fr)
OA (1) OA11653A (fr)
PA (1) PA8482001A1 (fr)
PE (1) PE20001084A1 (fr)
PL (1) PL346904A1 (fr)
SK (1) SK3592001A3 (fr)
TN (1) TNSN99177A1 (fr)
TR (2) TR200101357T2 (fr)
TW (1) TW518225B (fr)
WO (1) WO2000016777A1 (fr)
YU (1) YU21701A (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US7132287B2 (en) 2001-06-18 2006-11-07 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5HT-1A agonists
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
WO2005122767A1 (fr) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, notamment de l'uridine, utilisees dans des traitements sur des patients atteints de troubles bipolaires
EP1784199A4 (fr) * 2004-08-11 2010-06-23 Mclean Hospital Corp Compose pour le traitement de la dependance, de la suppression et de l'usage de la marijuana
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
PE20070523A1 (es) 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008083442A1 (fr) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Procédé pour la formulation de médicaments mixtes contre tdah
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
US11426366B2 (en) 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008148A1 (fr) * 1989-01-23 1990-07-26 Pfizer Inc. Agents anxiolytiques bis-aza-bicycliques
WO1992000075A1 (fr) * 1990-06-29 1992-01-09 Pfizer Inc. Derives de pyridopyrazine utilises dans le traitement de l'abus et de la dependance de substances
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
WO1995034555A1 (fr) * 1994-06-14 1995-12-21 Pfizer Inc. Derives de la benzimidazolone a activite dopaminergique centrale
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Also Published As

Publication number Publication date
NO20011409D0 (no) 2001-03-20
BR9913975A (pt) 2001-06-19
IL164839A0 (en) 2005-12-18
ID28028A (id) 2001-05-03
EE200100179A (et) 2002-10-15
CA2344670A1 (fr) 2000-03-30
GT199900154A (es) 2001-03-06
US20010034347A1 (en) 2001-10-25
AR029739A1 (es) 2003-07-16
KR20010075222A (ko) 2001-08-09
HUP0103691A2 (hu) 2002-02-28
TNSN99177A1 (fr) 2005-11-10
WO2000016777A1 (fr) 2000-03-30
IL141507A0 (en) 2002-03-10
GEP20033081B (en) 2003-10-27
IS5852A (is) 2001-02-20
PE20001084A1 (es) 2000-10-18
DZ2894A1 (fr) 2003-12-15
EA200100204A1 (ru) 2001-08-27
CN1319013A (zh) 2001-10-24
AU760230B2 (en) 2003-05-08
TR200402083T2 (tr) 2004-10-21
US6300329B1 (en) 2001-10-09
AP2001002102A0 (en) 2001-03-31
CZ20011006A3 (cs) 2001-09-12
JP2002526448A (ja) 2002-08-20
PA8482001A1 (es) 2000-05-24
PL346904A1 (en) 2002-03-11
OA11653A (en) 2004-12-08
EP1115402A1 (fr) 2001-07-18
AP1456A (en) 2005-09-30
MA26690A1 (fr) 2004-12-20
HUP0103691A3 (en) 2003-01-28
TW518225B (en) 2003-01-21
EA200301063A1 (ru) 2004-12-30
CO5140075A1 (es) 2002-03-22
KR100468340B1 (ko) 2005-01-27
HN1999000146A (es) 2000-11-11
YU21701A (sh) 2004-07-15
HRP20010209A2 (en) 2002-04-30
BG105445A (en) 2001-12-29
MY127939A (en) 2007-01-31
KR20040054752A (ko) 2004-06-25
KR20030088512A (ko) 2003-11-19
NO20011409L (no) 2001-03-28
US6608064B2 (en) 2003-08-19
TR200101357T2 (tr) 2001-08-21
NZ509855A (en) 2003-04-29
AU5383199A (en) 2000-04-10

Similar Documents

Publication Publication Date Title
SK3592001A3 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
Baladi et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor
Florin et al. Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment
US20020037926A1 (en) Sodium channel blocker compositions and the use thereof
Nikolic et al. Imidazoline antihypertensive drugs: selective i1‐imidazoline receptors activation
US5744476A (en) Dopamine D1 agonists for the treatment of dementia
US20070088074A1 (en) Article of manufacture comprising aromatic amino acids isomers, analogs, or derivatives thereof to treat neurological disorders involving dysfunction of glutamatergic synaptic transmission
JP2002541215A5 (fr)
US20040220184A1 (en) Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
Kuczenski et al. Regional norepinephrine response to amphetamine using dialysis: comparison with caudate dopamine
Angel et al. Involvement of alpha-2 adrenergic receptor subtypes in hyperglycemia.
US20070184490A1 (en) Neuronal nicotinic receptor ligands and their use
HRP20010584A2 (en) N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
Chan et al. Characterization of a KATP Channel—Independent Pathway Involved in Potentiation of Insulin Secretion by Efaroxan
MXPA01002946A (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
JP2007524620A (ja) 二重機能性化合物及びその使用
Ubaldi et al. Investigation of allyphenyline efficacy in the treatment of alcohol withdrawal symptoms
McBride et al. Spiroxatrine augments fluoxetine-induced reduction of ethanol intake by the P line of rats
Smyth et al. Effects of central and peripheral neuropeptide Y on sodium and water excretion in the rat
Halperin et al. Growth hormone response to guanfacine in boys with attention deficit hyperactivity disorder: a preliminary study
Grözinger et al. Antihistamines and sleep